Presentation and Outcomes of <scp>CNS</scp> Tumors Associated With Phakomatoses Syndromes From a Specialized Neuro‐Oncology Practice in India

Krishnan, Anuradha; Baviskar, Yamini; Chatterjee, Abhishek; Dasgupta, Archya; Epari, Sridhar; Sahu, Arpita; Chinnaswamy, Girish; Menon, Nandini; Moiyadi, Aliasgar; Gupta, Tejpal; Sastri‐Goda, Jayant

Presentation and Outcomes of <scp>CNS</scp> Tumors Associated With Phakomatoses Syndromes From a Specialized Neuro‐Oncology Practice in India

Abstract

ABSTRACT Purpose Phakomatoses‐associated primary central nervous system (CNS) tumors are therapeutically challenging due to young age of onset, multiple tumors, and prolonged morbidity from long‐term survival. This study evaluated demographics, survival, and prognostic factors of patients with phakomatoses‐associated CNS tumors treated at a specialized neuro‐oncology service in India. Materials and Methods Consecutive patients diagnosed and managed between 2000 and 2022 were included in this retrospective study. Data were retrieved from electronic medical records. Treatment decisions were multidisciplinary and included maximal safe resection, radiation (RT), and systemic therapy as indicated. Kaplan–Meier survival analysis evaluated overall survival (OS) and progression‐free survival (PFS). Univariate analyses used the log‐rank test, and multivariate analyses the restricted mean survival time. Results A total of 121 patients were analysed: NF1 (61.2%), NF2 (23.1%), VHL (10.7%), and TSC (5.0%). For NF1, median follow‐up was 36.5 months (95% CI: 1–254); 3‐year PFS and OS were 76.4% (95% CI: 66.5–87.8) and 87.7% (95% CI: 80.1–96.1) respectively. On univariate analysis, NF1 high‐grade glioma patients who did not receive RT had inferior outcomes, though not significant on RMST. For NF2, median follow‐up was 40.5 months (95% CI: 1–199); 5‐year PFS and OS were 37.3% (95% CI: 20.5–68.1) and 100% respectively. For VHL, median follow‐up was 66.5 months (95% CI: 3–426); 5‐year PFS and OS were 77.9% (95% CI: 54.6–100) and 100% respectively. For TSC, median follow‐up was 71 months (95% CI: 1–228); 5‐year PFS and OS were 75% (95% CI: 42.5–100) and 100% respectively. Conclusion Phakomatoses‐associated CNS tumors show promising outcomes with multimodality management. Further research into targeted multimodality treatment is warranted.

Meet DeepDyve

Get unlimited, instant access to over 150 million full-text scientific articles for less than the price of buying a single PDF.

150M+Research Papers

35M+Full-Text Streaming Papers

25M+Open Access Papers

$2/dayStarting Price

DeepDyve Collection

Access top-tier journals without the top-tier price. We partner directly with the world’s leading academic publishers to bring you legally compliant, instant access. Read the latest findings from Springer, Wiley, Oxford University Press, and more—all in one subscription.

Browse our collection of titles from leading publishers

AI Research Assistant

Accelerate your research with our advanced AI tools. Chat directly with your uploaded papers, and DeepDyve’s 50M+ LitStream and OA collections of full-text papers. AI responses come directly from the literature, footnoted and sourced, to provide the most authoritative and verifiable responses. AI outputs powered by OpenAI and Anthropic Claude. AI Smart Folders (coming soon)

Stop wasting time on paywalls, pirated sites and scattered journal portals

Streamline your research workflow with DeepDyve's comprehensive literature management solution for less than the price of buying a single PDF.

Try 1 month for $0